Risedronate Sodium Tablet, Delayed Release
Product Images NDC 59762-0407

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 59762-0407). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Following Chemical Structure Of Risedronate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Risedronate Sodium Tablet For Oral Administration Contains The Equivalent Of 35 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Risedronate Sodium 01)

The Following Chemical Structure Of Risedronate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Risedronate Sodium Tablet For Oral Administration Contains The Equivalent Of 35 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Risedronate Sodium 01)
FDA Label Image

Figure 1 (Risedronate Sodium 02)

Figure 1 (Risedronate Sodium 02)
The figure shows the cumulative incidence of nonvertebral osteoporosis-related fractures over 3 years for patients taking placebo and ACTONEL 5mg. The fractures are categorized by location, including the wrist, humerus, hip, pelvis, leg, and clavicle. The text "9% of Patients" is not related to the figure and may refer to a statistic in the accompanying text that is not included here.*
FDA Label Image

Principal Display Panelndc 59762-0407-4risedronate Sodiumdelayed-release Tablets35 mg4 Tabletsonce-a-weekrx Only (Risedronate Sodium 03)

Principal Display Panelndc 59762-0407-4risedronate Sodiumdelayed-release Tablets35 mg4 Tabletsonce-a-weekrx Only (Risedronate Sodium 03)
FDA Label Image

Risedronate Sodium 04

Risedronate Sodium 04

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.